Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 4, 2006, Pages 375-383

  Derosa, G ^a   D'Angelo, A ^a   Ragonesi, P D ^b   Ciccarelli, L ^a   Piccinni, M N ^a   Pricolo, F ^a   Salvadeo, S A T ^a   Montagna, L ^a   Gravina, A ^a   Ferrari, I ^a   Paniga, S ^a   Cicero, A F G ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Homocysteine; Lipoprotein (a); Metabolic syndrome; Metformin; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; EXPERIENCE; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDICAL PARAMETERS; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 33745939897     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00756.x     Document Type: Article

References (42)

1. National Cholesterol Education Program (NCEP) Expert Panel (2001) Summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel III). JAMA, 67, 2486-2497.
2. Marcovina M, Koschinsky ML (1998) Lipoprotein (a) as a risk factor for coronary artery disease. American Journal of Cardiology, 82, 57-66.
3. Glader CA, Birgander LS, Stendlund H et al. (2002) Is lipoprotein (a) a predictor for survival in patients with established coronary artery disease? Results fro a prospective patient cohort study in Northern Sweden. Journal of Internal Medicine, 252, 27-35.
4. Peltier M, Iannetta Peltier MC, Sarano ME, Lesbre J-PM, Colas J-L, Tribouilloy CM (2002) Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis. Chest, 1212, 1589-1594.
5. Misirli H, Somay G, Ozbal N, Yasar Erenoglu N et al. (2002) Relation of lipid and lipoprotein(a) to ischemic stroke. Journal of Clinical Neuroscience, 9, 127-132.
6. Nawawi HM, Muhajir M, Kian YC et al. (2002) Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein(a) levels in diabetic patients. Diabetes Research and Clinical Practice, 56, 221-227.
7. Maca TH, Ahmadi R, Dergfler K et al. (2002) Influence of lipoprotein(a) on restenosis after femoropoliteal percutaneous transluminal angioplasty in Type 2 diabetic patients. Diabetic Medicine, 19, 300-306.
8. Tarkun I, Cetinarslan B, Canturk Z (2002) Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: relationship to metabolic parameters and diabetic complications. Nutrition, Metabolism and Cardiovascular Diseases, 12, 1227-1231.
9. Herrmann W, Knapp JP (2002) Hyperhomocysteinemia: a new risk factor for degenerative diseases. Clinical Laboratory, 48, 471-481.
10. American Diabetes Association (2001) Screening for diabetes (position statement). Diabetes Care, 24 (Suppl.), S21-S24.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285, 2486-2497.
12. Guidelines Subcommittee (1999) World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Journal of Hypertension, 17, 151-183.
13. World Health Organization (1997) Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. Geneva: WHO.
14. American Diabetes Association (2001) Nutrition recommendations and principles for people with diabetes mellitus (position statement). Diabetes Care, 24 (Suppl.), S44-S47.
15. Matthews DR, Hosker JP, Rudenski AS et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
16. Bunn HF, Gabbay HK, Gallop PM (1978) The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science, 200, 21-27.
17. European Diabetes Policy Group (1999) A desktop guide to type 2 diabetes mellitus. Diabetic Medicine, 16, 716-730.
18. Heding LG (1972) Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia, 8, 260-266.
19. Klose S, Borner K (1978) Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner selective analyzer (GSA II). Journal of Clinical Chemistry and Clinical Biochemistry, 15, 121-130.
20. Wahlefeld AW (1974) Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU, ed. Methods of enzymatic analysis, 2nd English edn. New York: Academic Press, Inc, 18-31.
21. Havel RJ, Edr HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation, 34, 1345-1353.
22. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499-502.
23. Scanu AM, Scandian L (1991) Lipoprotein (a): structure, biology and clinical relevance. Advances in Internal Medicine, 36, 249-270.
24. Uterman G, Weber W (1987) Protein composition of lipoprotein (a). Journal of Clinical Investigation, 80, 458-465.
25. Araki A, Sako Y (1987) Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescence detection. Journal of Chromatography, 422, 43-52.
26. Winer BJ (1971) Statistical principles in experimental design, 2nd edn. New York: McGraw-Hill.
27. Biondi-Zoccai GG, Abbate A, Liuzzo G et al. (2003) Atherothrombosis, inflammation, and diabetes. Journal of the American College of Cardiology, 41, 1071-1077.
28. Abbott RD, Curb JD, Rodriguez BL et al. (2003) Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. Journal of Clinical Epidemiology, 56, 479-486.
29. Tsai AW, Cushman M, Rosamond WD et al. (2002) Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Archives of Internal Medicine, 162, 1182-1189.
30. Theuma P, Fonseca VA (2003) Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Current Diabetes Reports, 3, 248-254.
31. Liu S, Willett WC (2002) Dietary glycemic load and atherothrombotic risk. Current Atherosclerosis Reports, 4, 454-461.
32. Johnson JA, Simpson SH, Majumdar SR et al. (2002) Decreased mortality associated with the use of metformin compared with sulphanylurea monotherapy in type 2 diabetes. Diabetes Care, 25, 2244-2248.
33. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet, 253, 854-865.
34. The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346, 393-403.
35. Despres JP (2003) Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes & Metabolism, 29, 53-61.
36. Grant PJ (2003) Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes & Metabolism, 29, 44-52.
37. Ovalle F, Ovalle-Berúmen JF (2002) Thiazolidinediones: a review of their benefits and risks. Southern Medical Journal, 95, 1187-1194.
38. Boyle PJ, King AB, Olansky L et al. (2002) Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clinical Therapeutics, 24, 378-396.
39. Derosa G, Cicero AF, Gaddi A et al. (2004) Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clinical Therapeutics, 26, 744-754.
40. Derosa G, Cicero AFG, Gaddi A et al. (2005) A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in patients with the metabolic syndrome. Diabetes Research and Clinical Practice, 69, 5-13.
41. Koschinsky ML, Marcovina SM (2003) The relationship between lipoprotein(a) and the complications of diabetes mellitus. Acta Diabetologica, 40, 65-76.
42. Marcovina SM, Koschinsky ML (2003) Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Current Opinion in Lipidology, 14, 361-366.